APS6-45 is an orally active tumor-calibrated inhibitor (TCI). APS6-45 inhibits RAS/MAPK signaling and exhibits antitumor activity.
体外研究
APS6-45 (3-30 nM; 3 weeks) strongly suppresses TT human Medullary Thyroid Carcinoma (MTC) cells colony formation in a soft agar assay.
APS6-45 (1 μM; 1 h) strongly inhibits RAS pathway activity signaling in human MTC cell lines TT and MZ-CRC-1.
体内研究
APS6-45 (10 mg/kg; p.o. daily for 30 d) inhibits growth of TT tumors in mice and does not affect body weight.
APS6-45 (0.1-160 mg/kg; a single p.o.) does not cause detectable toxic effects in mice.
APS6-45 (20 mg/kg; a single p.o.) exhibits long half-life (5.6 h), Cmax (9.7 µM) and AUC0-24 (123.7 µM•h) in mice.
Animal Model:
Female nude mice (6 weeks) are implanted with TT cells
Dosage:
10 mg/kg
Administration:
P.o. daily for 30 days
Result:
Led to partial or complete responses in 75% and was well tolerated.
Animal Model:
Male ICR mice (6 weeks of age)
Dosage:
20 mg/kg (Pharmacokinetic Analysis)
Administration:
A single p.o.
Result:
T1/2=5.6 h, Cmax=9.7 µM, AUC0-24=123.7 µM•h.
分子式
C23H16F8N4O3
分子量
548.39
CAS号
2188236-41-9
运输条件
Room temperature in continental US; may vary elsewhere.